About This Trial

First-in-class activin signaling inhibitor as monotherapy for treatment-naive PAH.

Primary Endpoints

  • 6-minute walk distance
  • Time to clinical worsening

Latest Update

February 2026

FDA approved Winrevair (sotatercept) March 2024. HYPERION study exploring expanded use ongoing.